Reports
United States Vaccine Market: By Technology: Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics: SWOT Analysis; Competitive Landscape; Industry Events and Developments
United States Vaccine Market Outlook
The United States vaccine market attained a value of about USD 11.2 billion in 2020. The market is further expected to grow in the forecast period of 2023-2028 at a CAGR of 9.8%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Deployment of mRNA Technology in Vaccine Development is Aiding the Market Growth
The initiation of vaccine development through mRNA technology is increasing research and development (R&D) activities owing to the prevalence of various infectious diseases, such as Ebola, Zika, and influenza, among others. This trend has been fuelled due to the emergence of SARS-CoV-2, which is surging the requirement for effective vaccines to prevent morbidity and fatality, which has driven the market.
As research activities to develop efficient vaccines were initiated, mRNA technology was leveraged to easily modify the sequencing of vaccines to enable their effectiveness against the mutations of the novel virus, which has driven the market growth. Moreover, the development of mRNA vaccines against COVID-19 infections by leading companies, such as Pfizer and Moderna, has fuelled the market growth. The increasing approvals of the novel COVID-19 mRNA vaccines have provided further impetus to the market growth. For instance, the Food and Drug Administration of the United States authorised the emergency use of Pfizer’s mRNA vaccine, BNT162b2, in December 2020.
Vaccine: Market Segmentation
A vaccine is a medicine that enables the suspension of killed or weakened microbes to enable the development of antibodies and prevent the risk of contraction of infectious disease. It provides active immunity from diseases to enhance the quality of life. The administration of vaccines, variously known as vaccination, is one of the most effective ways to prevent the spread of infectious diseases.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The major technologies of vaccine are:
- Recombinant and Conjugate Vaccine
- Inactivated Vaccines
- Live Attenuated Vaccines
- Toxoid Vaccines
- Others
The market can be broadly categorised on the basis of its indications into:
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella, Measles, Mumps, and Rubella
- Diphtheria, Pertussis, and Tetanus (DPT)
- Polio
- Hepatitis
- Others
By end uses, the market is divided into:
- Paediatric Vaccine
- Adult Vaccine
- Travellers Vaccine
The EMR report looks into the regional markets of vaccine in the United States like New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Demand for Immunisation of Infants to Bolster the Market Growth of Vaccine in the United States
The rising demand for vaccines of pathogenic issues, diarrhoeal diseases, and parasitic adversaries, among others, is augmenting the industry growth. As the requirement of immunisation of infants to enhance the quality of life is surging, vaccines are increasingly deployed to prevent the risk of infectious diseases among children, hence fuelling the market growth. For instance, federally funded programs such as the Vaccines for Children (VFC) and Children’s Health Insurance Program (CHIP) offers free vaccination for underprivileged children. Moreover, the deployment of cutting-edge technologies to enable the swift development of vaccines is propelling the market growth.
The development of innovative vaccines that can be delivered through micro patches to enable efficient vaccination in infants is anticipated to augment the market growth. Advancements in biotechnology and genetic engineering are expected to lead to the determination of accurate structures of antigens, hence aiding in the development of more efficient vaccines. In addition, the increasing concerns regarding the resurgence of COVID-19 infections and the emergence of a novel virus are projected to propel the growth of the vaccine industry in the forecast period.
Key Industry Players in the United States Vaccine Market
The report presents a detailed analysis of the following key players in the United States vaccine market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi
- AstraZeneca plc
- Johnson & Johnson Services, Inc.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Technology, Indication, End Use, Region |
| Breakup by Technology | Recombinant and Conjugate Vaccine, Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Others |
| Breakup by Indication | Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DPT), Polio, Hepatitis, Others |
| Breakup by End Use | Paediatric Vaccine, Adult Vaccine, Travellers Vaccine |
| Breakup by Region | New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, Far West |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, Johnson & Johnson Services, Inc., Others |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 United States
7 Opportunities and Challenges in the Market
8 United States Vaccine Market Analysis
8.1 Key Industry Highlights
8.2 United States Vaccine Historical Market (2018-2022)
8.3 United States Vaccine Market Forecast (2023-2028)
8.4 United States Vaccine Market by Technology
8.4.1 Recombinant and Conjugate Vaccine
8.4.1.1 Historical Trend (2018-2022)
8.4.1.2 Forecast Trend (2023-2028)
8.4.2 Inactivated Vaccines
8.4.2.1 Historical Trend (2018-2022)
8.4.2.2 Forecast Trend (2023-2028)
8.4.3 Live Attenuated Vaccines
8.4.3.1 Historical Trend (2018-2022)
8.4.3.2 Forecast Trend (2023-2028)
8.4.4 Toxoid Vaccines
8.4.4.1 Historical Trend (2018-2022)
8.4.4.2 Forecast Trend (2023-2028)
8.4.5 Others
8.5 United States Vaccine Market by Indication
8.5.1 Pneumococcal Disease
8.5.1.1 Historical Trend (2018-2022)
8.5.1.2 Forecast Trend (2023-2028)
8.5.2 Influenza
8.5.2.1 Historical Trend (2018-2022)
8.5.2.2 Forecast Trend (2023-2028)
8.5.3 Human Papilloma Virus
8.5.3.1 Historical Trend (2018-2022)
8.5.3.2 Forecast Trend (2023-2028)
8.5.4 Meningococcal Disease
8.5.4.1 Historical Trend (2018-2022)
8.5.4.2 Forecast Trend (2023-2028)
8.5.5 Rotavirus
8.5.5.1 Historical Trend (2018-2022)
8.5.5.2 Forecast Trend (2023-2028)
8.5.6 Varicella, Measles, Mumps, and Rubella
8.5.6.1 Historical Trend (2018-2022)
8.5.6.2 Forecast Trend (2023-2028)
8.5.7 Diphtheria, Pertussis, and Tetanus (DPT)
8.5.7.1 Historical Trend (2018-2022)
8.5.7.2 Forecast Trend (2023-2028)
8.5.8 Polio
8.5.8.1 Historical Trend (2018-2022)
8.5.8.2 Forecast Trend (2023-2028)
8.5.9 Hepatitis
8.5.9.1 Historical Trend (2018-2022)
8.5.9.2 Forecast Trend (2023-2028)
8.5.10 Others
8.6 United States Vaccine Market by End Use
8.6.1 Paediatric Vaccine
8.6.1.1 Historical Trend (2018-2022)
8.6.1.2 Forecast Trend (2023-2028)
8.6.2 Adult Vaccine
8.6.2.1 Historical Trend (2018-2022)
8.6.2.2 Forecast Trend (2023-2028)
8.6.3 Travellers Vaccine
8.6.3.1 Historical Trend (2018-2022)
8.6.3.2 Forecast Trend (2023-2028)
8.7 United States Vaccine Market by Region
8.7.1 New England
8.7.2 Mideast
8.7.3 Great Lakes
8.7.4 Plains
8.7.5 Southeast
8.7.6 Southwest
8.7.7 Rocky Mountain
8.7.8 Far West
9 Regional Analysis
9.1 New England
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.2 Mideast
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.3 Great Lakes
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.4 Plains
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.5 Southeast
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.6 Southwest
9.6.1 Historical Trend (2018-2022)
9.6.2 Forecast Trend (2023-2028)
9.7 Rocky Mountain
9.7.1 Historical Trend (2018-2022)
9.7.2 Forecast Trend (2023-2028)
9.8 Far West
9.8.1 Historical Trend (2018-2022)
9.8.2 Forecast Trend (2023-2028)
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 GlaxoSmithKline plc
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Merck & Co., Inc.
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 Novartis AG
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Pfizer Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Sanofi
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 AstraZeneca plc
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Johnson & Johnson Services, Inc.
12.2.7.1 Company Overview
12.2.7.2 Product Portfolio
12.2.7.3 Demographic Reach and Achievements
12.2.7.4 Certifications
12.2.8 Others
13 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Market: Key Industry Highlights, 2018 and 2028
2. United States Vaccine Historical Market: Breakup by Technology (USD Million), 2018-2022
3. United States Vaccine Market Forecast: Breakup by Technology (USD Million), 2023-2028
4. United States Vaccine Historical Market: Breakup by Indication (USD Million), 2018-2022
5. United States Vaccine Market Forecast: Breakup by Indication (USD Million), 2023-2028
6. United States Vaccine Historical Market: Breakup by End Use (USD Million), 2018-2022
7. United States Vaccine Market Forecast: Breakup by End Use (USD Million), 2023-2028
8. United States Vaccine Historical Market: Breakup by Region (USD Million), 2018-2022
9. United States Vaccine Market Forecast: Breakup by Region (USD Million), 2023-2028
10. United States Vaccine Market Structure
Key Questions Answered in the Report
In 2020, the United States vaccine market attained a value of nearly USD 11.2 billion.
The market is projected to grow at a CAGR of 9.8% between 2021 and 2026.
The market is being aided by the rising use of mRNA technology in vaccine development, the surge of the COVID-19 crisis, and the increasing approvals of the novel COVID-19 mRNA vaccines.
The industry is expected to be augmented by the rising demand for immunisation of infants, the deployment of cutting-edge technology in vaccine development, and advancements in biotechnology and genetic engineering.
The major regions in the industry are New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West.
The major technologies of vaccine in the industry are recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others.
The significant indications in the market are pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, and hepatitis, among others.
The various end uses of vaccines are paediatric vaccine, adult vaccine, and travellers vaccine.
The major players in the industry are GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, and Johnson & Johnson Services, Inc., among others.
Analyst Review
The United States vaccine market attained a value of nearly USD 11.2 billion in 2020, driven by the rising use of mRNA technology in vaccine development. Aided by advancements in biotechnology and genetic engineering, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 9.8%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on its technologies, the vaccine industry can be segmented into recombinant and conjugate vaccine, inactivated vaccines, live attenuated vaccines, and toxoid vaccines, among others. On the basis of indication, the industry is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DPT), polio, and hepatitis, among others. By end use, the market is classified into paediatric vaccine, adult vaccine, and travellers vaccine. The major regional markets for vaccine in the United States are New England, Mideast, Great Lakes, Plains, Southeast, Southwest, Rocky Mountain, and Far West. The key players in the above market include GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, AstraZeneca plc, and Johnson & Johnson Services, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER